Fukata Mayuka, Omura Tomomi, Maeda Keiko, Mori Takako, Kato Hiroyuki, Kuzuya Masafumi
Department of Residency Training, Meitetsu Hospital, Nagoya, JPN.
Department of Geriatric and General Internal Medicine, Meitetsu Hospital, Nagoya, JPN.
Cureus. 2025 Jul 30;17(7):e89086. doi: 10.7759/cureus.89086. eCollection 2025 Jul.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used for the treatment of type 2 diabetes mellitus. Recently, their association with drug-induced bullous pemphigoid (BP) has attracted increasing attention. In this report, we present a case of an 84-year-old woman who developed BP after COVID-19 infection while taking a DPP-4 inhibitor. The temporal relationship between drug administration, viral infection, and onset of autoimmune disease indicates a possible interaction between COVID-19-induced immune dysregulation and DPP-4 inhibition. The coexistence of these factors may increase the risk of developing BP in older patients with diabetes, which warrants careful monitoring.
二肽基肽酶-4（DPP-4）抑制剂被广泛用于治疗2型糖尿病。最近，它们与药物性大疱性类天疱疮（BP）的关联引起了越来越多的关注。在本报告中，我们介绍了一例84岁女性患者，她在感染新冠病毒后服用DPP-4抑制剂期间发生了BP。药物给药、病毒感染和自身免疫性疾病发作之间的时间关系表明，新冠病毒诱导的免疫失调与DPP-4抑制之间可能存在相互作用。这些因素的共存可能会增加老年糖尿病患者发生BP的风险，这值得密切监测。
